EGFR/HER2 Mutant-selective Inhibitor HS-10376

Preferred Label : EGFR/HER2 Mutant-selective Inhibitor HS-10376;

NCIt synonyms : EGFR/HER2 Exon 20 Inhibitor HS-10376;

NCIt definition : An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), with potential antineoplastic activity. Upon oral administration, EGFR/HER2 mutant-selective inhibitor HS-10376 targets, binds to, and inhibits the activity of EGFR and HER2 with exon20 insertion mutations, thereby preventing EGFR- and HER2-mediated signaling. This may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization.;

Molecule name : HS-10376; HS 10376;

NCI Metathesaurus CUI : CL1794293;

Details

Origin ID

C189091;

UMLS CUI

C5706538;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- EGFR Exon 20 Insertion Mutation [NCIt concept]
- ERBB2 Exon 20 Insertion Mutation [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients